Author:
Ketchart Wannarasmi,Yeh I-Ju,Zhou Haoyan,Thiagarajan Praveena S.,Lathia Justin,Reizes Ofer,Exner Agata,Su Bin,Montano Monica M.
Reference41 articles.
1. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent;Andreeff;Blood,1992
2. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals;Young;Cancer Res,1988
3. Increased HEXIM1 expression during erythroleukemia and neuroblastoma cell differentiation;Turano;J. Cell. Physiol,2006
4. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580);Conley;Cancer Res,1989
5. Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation;He;Mol. Cell. Biol,2006
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献